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Tuberculosis (TB) is the most common opportunistic infection in 
HIV-infected people. In 2010 the association between these diseases 
resulted in up to 1.2 million (12 - 14%) new TB cases among HIV-
infected people and the death of 0.35 million HIV/TB co-infected 
patients.1 The scale-up of combination antiretroviral therapy (cART) 
in the developing world is rapidly progressing, improving survival 
of HIV-infected people. While cART effectively reduces TB risk 
in HIV-infected persons,2 TB-associated immune reconstitution 
inflammatory syndrome (TB-IRIS) has emerged as an important 
early cART complication, reflecting that TB immune responses 
contribute to both protection and pathology. Two TB-IRIS forms are 
recognised: (i) paradoxical, in patients established on TB treatment 
before cART, who manifest with recurrent or new TB symptoms and 
clinical features after cART initiation; and (ii) lesser-characterised 
unmasking TB-IRIS, in patients not receiving treatment for TB when 
cART is started, but who present with active TB within 3 months of 
initiation, with heightened intensity of clinical manifestations, and 
marked inflammatory features.3,4 
Recently we studied the regenerating TB-specific T-cell immune 
responses in Mycobacterium tuberculosis (MTB)-sensitised adults 
over 12 months following commencement of cART. We showed 
that, in overall improved TB antigen-specific immunity, it is the 
central memory T-cell response that best correlates with increased 
cART-mediated immunity.5 A single patient in this cohort – 
excluded from analysis – was diagnosed with overt pulmonary TB 
having commenced cART. We were therefore presented with the 
opportunity to undertake detailed immunological analysis of a 
case that we considered as unmasking TB-IRIS. Tuberculin-specific 
Th1-responses were expanded during, but not before, the IRIS 
episode. We found a distorted balance between central memory and 
effector memory T-cells at cART commencement that might have 
predisposed the patient to unmasking TB-IRIS.
Methods
The study was approved by the University of Cape Town Faculty of 
Health Sciences Human Research Ethics Committee (FHS HREC 
336/2004). HIV-infected adults were recruited at G F Jooste Hospital 
(GFJH), Cape Town, at the start of cART (day 0), and followed up at 
weeks 2, 4, 12, 24, 36 and 48, as described in detail.5 Venous blood (30 
ml) was obtained at each time-point for separating peripheral blood 
mononuclear cells (PBMC) and serum. 
For comparison in some instances we included a subset of 5 
patients (3 female, 2 male, median age 36 years, median nadir 
CD4 count 42), recruited for a previously published prospective 
longitudinal study;6 all developed paradoxical TB-IRIS within a 
median of 14 days of commencing cART. 
T-cell phenotyping was performed using fresh PBMC following 
overnight stimulation with purified protein derivative (PPD; Statens 
Serum Institute, Denmark) and staining for various cell-surface 
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Background. Tuberculosis-associated immune reconstitution 
inflammatory syndrome (TB-IRIS) is an early complication 
of combination antiretroviral therapy (cART). Two forms are 
recognised: (i) paradoxical – recurrent or new TB symptoms 
develop after cART initiation in patients receiving TB treatment 
prior to cART; and (ii) unmasking TB-IRIS – active TB presents 
within 3 months of cART in patients not receiving TB treatment at 
cART initiation. The latter has heightened clinical manifestations 
and a marked inflammatory presentation.
Aim. To gain insight into the immune pathogenesis of a case of 
unmasking TB-IRIS. 
Methods. The patient was recruited when starting cART and 
followed up at 4, 12 and 24 weeks of treatment. Peripheral blood 
mononuclear cells were used for flow cytometry.
Results. Immunological analysis indicated increased CD4+ T-cell 
proportions from 1.1% at baseline to 14% at 24 weeks (the CD4 
count increased from 4 cells/µl at baseline to 41 cells/µl at 24 weeks). 
HIV viral load fell from 460 774 to 1 405 copies/ml during the same 
period. The proportion of TB antigen (PPD)-specific CD4+IFN-γ+ 
cells increased from 0.4% at baseline and 4 weeks (IRIS onset) to 
7.8% at 12 weeks (after resolution of the IRIS episode); this fell 
to 0.7% at 24 weeks. The surface phenotype of CD4+IFN-γ+ cells 
during the episode was CD45RO+, CD45RA-, CCR7-, CD62L-, 
CCR5+/- and CD69-. We found a distorted balance between central 
memory and effector memory T-cells at cART commencement 
that might have predisposed the patient to unmasking TB-IRIS. We 
showed that this might have reflected compromised thymic output.
Discussion. While it has been suggested that tuberculin-specific 
Th1-responses induce TB-IRIS in HIV co-infected patients, our 
data in this case indicated that these cells were expanded only after 
IRIS onset and were therefore not inducing TB-IRIS.
Conclusion. We describe, in hitherto unpublished detail, the 
immunological characterisation of an unmasking TB-IRIS case; we 
show that thymic output may be compromised at IRIS onset.
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markers and intracellular cytokines as described,5 using a BD FACS 
Calibur Flow Cytometer. Data analysis was performed using FlowJo 
Cytometry Analysis software (TreeStar Inc, Stanford University, 
FlowJo Africa scheme). 
Serum thymulin was determined by enzyme-linked immunosorbent 
assay (ELISA) (PromoKine, PromoCell Gmbh, Germany) according 
to the manufacturer’s recommendations. 
Statistical analysis was performed using GraphPad Prism (version 
5.0a). Data normality was assessed with the D’Agostino & Pearson 
test. Results are quoted as medians with inter-quartile range (IQR). 
Results 
Patient clinical characterisation
The subject of the current report, one of 28 in our previous study,5 
was a 34-year-old male diagnosed with HIV infection in 2005 
and treated for pulmonary TB in primary care from September 
2005 to April 2006. He was referred to GFJH in March 2006 on 
diagnosis of cryptococcal meningitis, and treated with a 2-week 
course of amphotericin-B and flucytosine, followed by maintenance 
fluconazole. In May 2006 he commenced cART and was recruited to 
our longitudinal study.5 His CD4 count prior to cART was 4 cells/µl 
and HIV viral load was 460 774 copies/ml.
The patient reported no symptoms on the day of commencement 
of cART: stavudine 30 mg 12-hourly, lamivudine 150 mg 12-hourly 
and efavirenz 600 mg nocte. He reported no new symptoms and good 
cART adherence 2 weeks after initiation. However, at week 4 he showed 
symptoms of active TB: a productive cough, progressive dyspnoea on 
exertion of 6 days’ duration and diarrhoea, 3 kg of weight loss in 
2 weeks (weight 48.5 kg), febrile and pale appearance, respiratory 
distress, and hepatomegaly. A chest radiograph showed bilateral 
extensive mid-zone infiltrates and right hilar lymphadenopathy. 
Sputum direct microscopy (3+ acid-fast bacilli) confirmed MTB and 
the culture was positive (susceptible to rifampicin and isoniazid). 
He was admitted to GFJH and recommenced on anti-TB therapy 
(isoniazid, rifampicin, ethambutol, pyrazinamide and streptomycin 
initially). Corticosteroids were not prescribed. His symptoms 
resolved within 2 weeks: 12 weeks post cART initiation he weighed 
50.5 kg and his CD4 count increased to 38 cells/mm3; by 24 weeks his 
weight increased to 56 kg, his CD4 count to 41 cells/mm3 and his HIV 
viral load decreased to 1 405 copies/ml. 
Immunological characterisation
Immunophenotyping by flow cytometry was undertaken at day 0, 
and 2, 4, 12 and 24 weeks post cART initiation (Table 1). Results are 
presented as a comparison with the median and IQR values from the 
19-patient comparison group previously described.5
The patient started cART with a very low CD4 count (4 cells/mm3), 
reflected by the CD4+ T-cell proportions in flow cytometry: 1.1% of 
PBMC were positive for CD4 on day 0, remaining lower than the 
median of the comparison group up until 24 weeks, when it became 
similar at 14%. On the other hand, the proportion of CD8+ T-cells (% 
of PBMC) was comparable to and within the IQR of the comparison 
group at day 0, 2 and 4 weeks of cART. Interestingly, at 12 weeks (after 
the IRIS episode) the patient’s CD8+ T-cell proportions fell to just 
27.4%, rising again to 53% at 24 weeks. 
Cellular phenotypes in the peripheral blood
The proportion of effector CD4+CCR5+ T-cells was relatively high 
(Table 1): 11.8% on day 0, falling to 0.5% at 4 weeks, and a large 
expansion to 53.9% at 12 weeks. These dynamic changes were also 
reflected in proportional changes of differentiated CD4 cells that lack 
CD27 and CCR7, expanding to 72.3% at 12 weeks. 
The less differentiated central memory cells, as assessed by 2 
combinations of cell surface markers, expanded earlier at 4 weeks 
of cART (the time of IRIS onset): CD4+CD27+CD45RA- to 78.2% 
and CD4+CD27+CCR5- to 71.4%. After IRIS resolution at 12 weeks, 
these cells had proportionally and sharply declined to 14.7 and 13%, 
respectively, well below the median observed in the comparison 
group. 
The least differentiated CD27+CD45RA+ CD4+ T-cells were 
proportionally elevated at cART initiation (27% at day 0, double the 
13.1% median of the comparison group) and fell to 2.9% at week 4 
(IRIS onset). This was followed by a slow increase to 6.9% at week 12 
and a large expansion to 42% at week 24. 
Cellular activation was increased in the patient’s blood from 
day 0, with CD4+CD69+ cells reaching a peak of 19.4% at 4 weeks 
(IRIS onset), remaining elevated at week 12 (10.7%), and declining 
to levels similar to the comparison group by week 24 (Table 
1). Similarly, CD4+CD25+ T-cells were proportionally elevated at 
weeks 4 (3.8%) and 12 (6.6%), with a further increase to 9.9% 
at week 24. The proportion of CD4+CD25+ T-cells expressing 
interleukin (IL)-10 (regulatory cells) was slightly elevated from the 
start of cART and increased to 5.3% at 12 weeks, compared with the 
almost undetectable levels in the comparison group throughout the 
longitudinal follow-up. 
PPD-specific cytokine-producing T-cells during IRIS
Effector function of the CD4+ T-cells, determined by intracellular 
cytokine staining for IFN-γ in response to PPD stimulation, was 
found to be only 0.4% at cART initiation, remaining at similar levels 
at weeks 2 and 4 (when IRIS was diagnosed). However, there was an 
increase to 7.8% at week 12, in line with the expansion of effector 
CD4+CCR5+ and terminally differentiated effector CD4+CD27-
CCR7- T-cells. The proportion of PPD-specific CD4+IFN-γ+ T-cells 
returned to 0.7% at 24 weeks of cART, within the range seen in the 
19 unaffected patients (comparison group). Staining for CD45RO 
indicated that these cells were of memory phenotype (Table 1). 
Further surface phenotype analysis of the expanded CD4+IFN-γ+ 
T-cells at 12 weeks showed CD45RA-, CCR7-, CD62L-, CCR5+/- and 
CD69- (Fig. 1). Staining for additional cytokines indicated that 
CD4+ cells positive for the IL-2, IL-10 and TNF were all expanded 
at week 12 to 7.7%, 8.9% and 8.5%, respectively. CD4+IL-2+ cells 
were proportionally elevated at week 4 (4.8%, compared with the 
0.3% median in the comparison group), in line with the central 
memory CD4 T-cell expansion. Moreover, the cytokine-positive 
CD4+ T-cells displayed a poly-functional phenotype by expressing 
different combinations of IL-2, TNF and IL-10 (Fig. 2). CD4+TNF+ 
T-cells were proportionally elevated in the patient’s blood from the 
time of cART initiation (1.6%), indicating a distinct inflammatory 
component (Table 1).
Distorted balance between CD4 memory phenotypes 
The overall dynamics of CD4 T-cell phenotypes indicated that, 
between cART initiation and IRIS onset, the central memory T-cells 
proportionally and rapidly increased and effector T-cells proportionally 
fell, leading to a distorted balance between T-cell phenotypes. The 
ratio between the 2 subsets (% CD4+CD27+CD45RA-/% CD4+CCR5+ 
cells)(Fig. 3A) indicated a rise from 1.1 at day 0 to 156 at week 4 
(IRIS onset), and a fall to 0.3 at 12 weeks (after IRIS resolution). The 
comparative median ratios in the comparison group were relatively 
stable over time (7, 7.2 and 9.7 at weeks 0, 4 and 12, respectively). 
The least differentiated CD27+CD45RA+CD4+ T-cells were 
proportionally over-represented in the patient’s blood at cART 
initiation (27%), compared with the 19 patients who did not develop 
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TB during the first year of cART (Table 1). We hypothesised that this 
could be due to increased T-cell turnover as a result of decreased 
thymic output, as previously suggested.7 Thymic output can be 
approximated through the ratio of naïve/memory T-cells.8 We found 
the ratio of percentage CD4+CD27+CD45RA+/CD4+CD27+CD45RA- 
to be 2.1 at baseline (compared with median 0.3 in the comparison 
group) and 0.04 at 4 weeks (IRIS onset) (Fig. 3B). 
For further investigation, an alternative method of quantifying 
thymic output was employed. Thymulin (formerly called serum 
thymic factor) is a nonapeptide hormone secreted by human thymic 
epithelial cells and is essential for T-cell differentiation.9 Its production 
is stimulated by prolactin and growth hormones and it is detectable 
in serum by ELISA.10 The serum thymulin concentration in 13/19 
patients with no adverse events during cART was higher (median 406 
pg/ml, IQR 356 - 507) than that of the unmasking TB-IRIS patient at 
week 4 (223 pg/ml; Fig. 4A). 
We confirmed this finding by determining serum thymulin 
concentrations in 5 patients, previously recruited for a prospective 
longitudinal analysis,6 all of whom developed paradoxical TB-IRIS 
within 14 days of cART commencement. We found significantly 
lower serum thymulin concentrations in TB-IRIS patients at the 
time of IRIS compared with baseline levels (Fig. 4B): 382 pg/ml (IQR 
323 - 441 pg/ml) at day 0 v. 316 pg/ml (IQR 248 - 386 pg/ml) at day 
14 (p=0.03, Wilcoxon-matched pairs test). Further comparison of 
the 19-patient group with no adverse events (representing protective 
immune reconstitution) with the group with TB-IRIS (representing 
Table 1. Cellular phenotyping by flow cytometry in the peripheral blood of the unmasking TB-IRIS case* 
Proportion of PBMC (%)
Duration of cART
Day 0 Week 2 Week 4‡ Week 12§ Week 24
CD4+ Median 8.3 (2 - 12) 10.9 (6 - 15) 10.5 (8 - 15) 9.5 (8 - 15) 14.4 (9 - 22)
Case 1.1† 1.3 3.6 2.2 14.5
CD8+ Median 55 (39 - 61) 56 (42 - 66) 54 (46 - 68) 51 (40 - 65) 56 (48 - 63)
Case 46.1 46.9 59.3 27.4 53.4
CD4+CCR5+ Median 5.8 (3 - 11.9) 5.7 (4.1 - 15.2) 5.2 (2.1 - 23) 5.1 (3 - 13.4) 4.5 (1.2 - 5.8)
Case 11.8 7.3 0.5 53.9 2.0
CD4+CD27-CCR7- Median 42.9 (22 - 84) 36.6 (22 - 46) 39.3 (20 - 66) 33.7 (18.5 - 57) 23.2 (15 - 39)
Case 69.1 57.4 32.8 72.3 21.0
CD4+CD27+CD45RA- Median 40.6 (18 - 49) 40.6 (23 - 49) 37.4 (27 - 56) 49.5 (35 - 61) 45.0 (39 - 60)
Case 12.9 27.7 78.2 14.7 38.8
CD4+CD27+CCR5- Median 60.4 (25 - 81) 58.2 (37 - 81) 61.8 (32 - 77) 64.2 (32.5 - 74) 74.6 (58.5 - 80)
Case 27.2 43.1 71.4 13.0 76.6
CD4+CD27+CD45RA+ Median 13.1 (7.4 - 23.1) 15.9 (8.6 - 33.6) 14.4 (7.3 - 36) 11.1 (4.1 - 20.5) 22.6 (9 - 36)
Case 27.0 25.2 2.9 6.9 42.2
CD4+CD69+ Median 1.7 (1.5 - 3.9) 1.6 (0.9 - 2.6) 1.4 (1.1 - 1.9) 1.8 (1.3 - 4.9) 1.4 (1.2 - 1.8)
Case 6.3 4.8 19.4 10.7 0.5
CD4+CD25+ Median 2.3 (0.9 - 6.6) 3.6 (1.7 - 5.4) 1.1 (0.5 - 2.6) 3.1 (1.4 - 5.1) 1.3 (0.9 - 2.6)
Case 2.1 2.4 3.8 6.6 9.9
CD4+CD25+IL10+ Median 0.1 (0.03-0.3) 0.1 (0.03-0.11) 0.1 (0.02-0.2) 0.1 (0.03-0.2) 0 (0.02 - 0.1)
Case 0.9 0.9 0.2 5.3 0.03
CD4+IFN-γ+ Median 0.9 (0.3 - 1.4) 0.8 (0.5 - 1.3) 0.6 (0.3 - 1.4) 0.5 (0.3 - 0.9) 0.4 (0.2 - 0.9)
Case 0.4 0.4 0.4 7.8 0.7
CD4+IFN-γ+CD45RO+ Median 0.5 (0.1 - 0.7) 0.3 (0.1 - 0.9) 0.4 (0.2 - 0.6) 0.4 (0.1 - 1.1) 0.2 (0.1 - 0.9)
Case 0.3 0.7 0.3 7.9 0.7
CD4+IL2+ Median 0.4 (0.8 - 1.3) 1.1 (0.3 - 4.1) 0.3 (0.2 - 1.0) 0.4 (0.2 - 0.9) 0.2 (0.1 - 0.6)
Case 0.7 2.8 4.8 7.7 0.4
CD4+IL10+ Median 0.4 (0.2 - 0.8) 0.6 (0.2 - 3.1) 0.4 (0.3 - 0.8) 0.4 (0.3 - 0.9) 0.2 (0.1 - 0.5)
Case 2.1 3.1 5.1 8.9 0.4
CD4+TNF+ Median 0.3 (0.2 - 1.1) 0.3 (0.1 - 1.2) 0.4 (0.2 - 0.8) 0.5 (0.3 - 1.1) 0.2 (0.1 - 1.0)
Case 1.6 1.4 1.0 8.5 0.8
*Expressed as % specific cell type compared with the median (IQR) of a previously-described 19-patient comparison group. 
†Values in bold indicate those parameters that fall outside of the IQR of the median values observed in the comparison group.
‡IRIS onset. 
§After IRIS resolution.
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pathogenic immune reconstitution) indicated that, while there was 
no difference in thymulin concentrations at baseline (p=0.23, day 0), 
there was a significant difference between the groups at IRIS onset 
(p=0.009, day 14). Overall, these data indicate that thymic output may 
be significantly compromised at IRIS onset. 
Discussion
TB is the most common opportunistic infection in HIV-infected 
patients in Africa and reaches its highest incidence within the 
first 3 months of cART commencement. It has been proposed 
that all TB diagnosed when 
ART is concurrent should be 
termed ART-associated TB.11 
However, TB that presents 
soon after ART initiation due 
to restoration of TB antigen-
specific immune responses has 
been termed ‘unmasking TB’, 
and a subset of these patients 
presenting with heightened 
clinical manifestations 
within the first 3 months of 
ART are regarded as having 
‘unmasking TB-IRIS’.2 There 
have been less cases of 
unmasking TB-IRIS reported 
compared with paradoxical 
TB-IRIS, due to difficulties in 
diagnosis. It is accepted that 
TB-IRIS is a clinical syndrome 
resulting from the exaggerated 
inflammatory response 
towards the antigens of MTB 
in the context of a recovering 
immune response. However, 
the immunopathogenesis of 
this immune reaction is less 
well understood. 
Although the immuno-
pathogenesis of paradoxical 
TB-IRIS has been related to 
the expansion of PPD-specific 
IFN-γ-secreting CD4 T-cells 
during cART, we described 
similar CD4 T-cell expansions 
in TB-IRIS and non-IRIS 
control patients, bringing into 
question the causality of these 
expansions.6 
The present case presented 
a unique opportunity 
to elucidate further the 
immunopathogenesis of 
unmasking TB-IRIS. Our data 
show that the PPD-specific 
IFN-γ-secreting CD4 T-cells 
expanded after resolution of 
the IRIS episode (at 12 weeks, 
when the patient improved). 
T-cells undergo a unique 
developmental programme 
after activation, resulting in the generation of memory and effector T-cells. 
The sequence of differentiation remains unclear in humans but telomere 
length supports a linear pathway.12 Macaque studies also support the 
linear differentiation pathway from naïve, to central memory, to effector 
memory, with terminally differentiated cells representing the end stage.13 
Our data show a relatively large proportion of undifferentiated CD4 
T-cells at the time of cART initiation, leading on to the expansion of 
central memory cells at 4 weeks, and subsequent expansion of effector 
and terminally differentiated effector cells at 12 weeks. This coincides with 
the expansion of effector function (cytokine secretion) with intracellular 
Fig. 1. Flow cytometry plots illustrating the surface phenotype of CD4+IFN-γ+ cells at 12 weeks of cART (8 weeks 
after IRIS onset). CD4+ lymphocytes were selected and gated on intracellular IFN-γ (y-axes) and the surface markers 
CD45RO, CD45RA, CCR5, CCR7, CD62L and CD69 (illustrated on the x-axes).
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staining being highest for all 
4 cytokines studied (IFN-γ, 
IL-2, IL-10 and TNF) at 12 
weeks. The Th1 expansions 
associated with this case of 
unmasking TB-IRIS appear 
to be a consequence of the 
syndrome, and possibly due 
to the distorted proportional 
balance between memory 
T-cell phenotypes at the 
time of staring cART. Only 
the blood compartment 
was studied in this patient; 
therefore, we cannot 
exclude that the distorted 
balance is not attributed 
to sequestration in 
mycobacterial infection 
sites.
It is widely accepted 
that patients with high 
viral loads and low CD4 
counts are at the highest 
risk of developing all 
forms of TB-IRIS.2,11 
Studies of T-cell dynamics 
during HIV infection have 
shown that the higher 
the viral load, the greater 
the rate of CD4 T-cell 
destruction, hence the 
requirement for immune 
system reconstitution; 
this is dependent on the 
reconstitution of naïve 
CD4 T-cells, which in 
turn depends on thymic 
output.7 HIV-infected 
patients receiving cART 
and undergoing protective 
immune reconstitution, 
show a progressive 
increase in naïve T-cell 
numbers related to thymic 
function.14 A quantitative 
measure of thymic function 
is achieved by assaying the 
nonapeptide hormone 
thymulin produced by 
thymic epithelial cells.9 
HIV-infected individuals 
show a progressive decline of circulating thymulin levels.15 Here 
we show that the serum thymulin concentration was higher in 
patients with protective immune reconstitution, compared with this 
unmasking TB-IRIS case, especially at the time of IRIS diagnosis. 
We further confirmed in a larger group of patients with pathogenic 
immune reconstitution that thymic function is significantly 
compromised at the time of IRIS onset, as reflected by lower serum 
thymulin concentrations. Serum thymulin concentration in patients 
at highest risk for developing TB-IRIS warrants further study. 
There are several limitations to our study: (i) the absence of 
MTB culture at the end of the initial course of TB treatment to 
confirm treatment success, (ii) the lack of viral load at time-
points other than at day 0 and 6 months of cART, and (iii) the 
lack of longitudinal follow-up beyond 6 months. However, the 
marked inflammatory component, as illustrated by the expansion 
of activation and inflammatory markers (CD69 and TNF) on 
CD4 T-cells, supports the diagnosis of unmasking TB-IRIS in 
our study. 
Fig. 2. Flow cytometry plots illustrating the intracellular cytokine-secreting phenotype of CD4+ cells at 12 weeks of cART (8 
weeks after IRIS onset). CD4+ lymphocytes were selected and gated on intracellular cytokines IL-2, TNF and IL-10.
Fig. 4. (A) Longitudinal evaluation of serum thymulin concentration in 13 patients with no adverse events during cART 
(open circles) compared with the unmasking TB-IRIS case (illustrated in red). (B) Comparison of the same 13 patients (no 
IRIS, open circles) with 5 paradoxical TB-IRIS patients (IRIS, black circles) and the unmasking TB-IRIS case (red) at day 
0 and 14 of cART.
A B
Fig. 3. Evaluation of the ratio between (A) central memory and effector cells as calculated by percentage CD4+CD27+CD45RA-/
CD4+CCR5+ cells for each patient; and (B) naïve and memory cells calculated by percentage CD4+CD27+CD45RA+/
CD4+CD27+CD45RA- for each patient. The unmasking TB-IRIS case is illustrated in red.
A B
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Conclusion
We describe, in hitherto unpublished detail, the immunological 
characterisation of an unmasking TB-IRIS case, showing that immune 
changes may be linked to the distorted homeostatic balance between 
T-cell memory phenotypes at the time of cART initiation. We provide 
evidence that this distorted balance may reflect compromised thymic 
output in patients who are most at risk of developing immune 
reconstitution disease. 
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